source
- Intellia CRISPR drug succeeds in late-stage study against rare swelling disorderThe findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.BioPharma Dive · 3mo ago↗ source
- What’s the true risk for eating disorders with GLP-1s?The state of Covid-19 in 2026, a hat to treat depression, and other health news from Morning RoundsSTAT · 3mo ago↗ source
- STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trialWith good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?STAT · 3mo ago